PD-L1 Expression (CPS >= 1)

mutation class

Gene Expression

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

121 sites for NCT04660344

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Infiltrating Bladder Urothelial Carcinoma

atezolizumab

immunotherapy

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

116 sites for NCT04740918

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

207 sites for NCT04513925

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

1 site for NCT04969861

PD-L1 Expression (CPS >= 1)

Head and Neck Squamous Cell Carcinoma

bempegaldesleukin, +1 more drug

immunotherapy, +1 more type

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

7 sites for NCT05063552

PD-L1 Expression (CPS >= 1)

Head and Neck Squamous Cell Carcinoma

atezolizumab, +6 more drugs

chemotherapy, +2 more types

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

61 sites for NCT04671667

PD-L1 Expression (CPS >= 1)

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

pembrolizumab, +1 more drug

immunotherapy, +1 more type

Show 48 Trials for PD-L1 Expression (CPS >= 1)

pembrolizumab + chemotherapy +/- bevacizumab

PD-L1 Expression (CPS >= 1)

Cervical Carcinoma